Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 10/2018

01-10-2018 | Letter to the Editor

Author’s Reply to Reith: “Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults”

Authors: Anne van Rongen, Johannes N. van den Anker, Catherijne A. J. Knibbe

Published in: Clinical Pharmacokinetics | Issue 10/2018

Login to get access

Excerpt

Dear Editor, …
Literature
1.
2.
van Rongen A, Brill MJE, Vaughns JD, Valitalo PAJ, van Dongen EPA, van Ramshorst B, et al. Higher midazolam clearance in obese adolescents compared with morbidly obese adults. Clin Pharmacokinet. 2018;57(5):601–11.CrossRefPubMed
3.
Brill MJ, van Rongen A, Houwink AP, Burggraaf J, van Ramshorst B, Wiezer RJ, et al. Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers. Clin Pharmacokinet. 2014;53(12):931–41.CrossRefPubMedPubMedCentral
4.
Liu Y, Cao W, Liu Y, Wang Y, Lang R, Yue Y. Changes in duration of action of rocuronium following decrease in hepatic blood flow during pneumoperitoneum for laparoscopic gynaecological surgery. BMC Anesthesiol. 2017;17(1):45.CrossRefPubMedPubMedCentral
5.
Brill MJ, van Rongen A, van Dongen EP, van Ramshorst B, Hazebroek EJ, Darwich AS, et al. The pharmacokinetics of the CYP3A substrate midazolam in morbidly obese patients before and one year after bariatric surgery. Pharm Res. 2015;32(12):3927–36.CrossRefPubMedPubMedCentral
6.
Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology. 1984;61(13):27–35.CrossRefPubMed
7.
Thummel KE, O’Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther. 1996;59(10):491–502.CrossRefPubMed
8.
Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, Frye RF. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther. 2002;72(8):718–28.CrossRefPubMed
9.
Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther. 1992;51(24):715–28.CrossRefPubMed
10.
Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol. 1994;47(9):1643–53.CrossRefPubMed
11.
Shord SS, Chan LN, Camp JR, Vasquez EM, Jeong HY, Molokie RE, et al. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. Br J Clin Pharmacol. 2010;69(2):160–6.CrossRefPubMedPubMedCentral
12.
van Gerven JM, Roncari G, Schoemaker RC, Massarella J, Keesmaat P, Kooyman H. Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. Br J Clin Pharmacol. 1997;44(5):487–93.CrossRefPubMedPubMedCentral
Metadata
Title
Author’s Reply to Reith: “Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults”
Authors
Anne van Rongen
Johannes N. van den Anker
Catherijne A. J. Knibbe
Publication date
01-10-2018
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 10/2018
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-018-0692-z

Other articles of this Issue 10/2018

Clinical Pharmacokinetics 10/2018 Go to the issue

Original Research Article

Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration–Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics

Review article

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics

Original Research Article

Polymorphic Expression of UGT1A9 is Associated with Variable Acetaminophen Glucuronidation in Neonates: A Population Pharmacokinetic and Pharmacogenetic Study

Review Article

Treosulfan Pharmacokinetics and its Variability in Pediatric and Adult Patients Undergoing Conditioning Prior to Hematopoietic Stem Cell Transplantation: Current State of the Art, In-Depth Analysis, and Perspectives

Original Research Article

Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis

Letter to the Editor

Comment on van Rongen et al., “Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults”